An observational study in Heart Failure and Atrial Fibrillation (AF), sponsored by Bursa Postgraduate Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Bursa Postgraduate Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Heart Failure with a site in Turkey — 27 open to participants now, 38 under way, 13 of them phase 3. Heart Failure · Turkey.
Among the 131 studies in Heart Failure with a site in Turkey, this one is the 23rd largest by enrollment of the 44 observational ones that give a count, is one of 12 that started in 2021, is one of 44 observational ones, and was the 131st registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →27 of the 131 studies in Heart Failure with a site in Turkey are open now. Recruiting first, the newest first:
Dokuz Eylul University · Sites in Turkey
Ages 18+
AstraZeneca · Sites in Turkey, United States, Argentina and 29 more countries
Ages 18+
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 40+
Bayer · Sites in Turkey, United States, Argentina and 20 more countries
Ages up to 18
Novo Nordisk A/S · Sites in Turkey, United States, Argentina and 24 more countries
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 36 · Phase 4 5
First in 2003; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is below the median of 200 across 1,985 observational studies indexed under Heart Failure.
Median enrollment 111 across the 87 interventional studies, 101 across the 44 observational. Of the 82 that completed or were terminated, 27 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 131 have an industry lead sponsor. The 10 most frequent:
Bursa Postgraduate Hospital is the lead sponsor of 16 studies on the registry; none are open to participants now.
Bursa Postgraduate Hospital has 3 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
9 of the studies in Heart Failure with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07752706Istanbul University - CerrahpasaBreathing Exercises for Dyspnea and Anxiety in Heart Failure | 2026-12-05 |
| NCT06707220Baskent UniversityThe Türkiye Heart Failure Registry | 2027-01 |
| NCT07420088Erol Olcok Corum Training and Research HospitalSeasonal Physical Activity in Patients With Heart Failure With Cardiac Implantable Electronic Devices | 2027-01-21 |
| NCT06747689Dokuz Eylul UniversityAssociation Between Sleep Quality and Self-Care in Heart Failure Patients | 2027-05-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 131 studies in Heart Failure with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study included 100 patients with persistent AF, heart failure (left ventricular ejection fraction 30-60%), and iron deficiency who underwent successful electrical cardioversion. Iron deficiency was defined as ferritin \<100 ng/mL or 100-299 ng/mL with transferrin saturation \<20%. Fifty patients received 1000 mg intravenous FCM immediately before cardioversion, while 50 served as controls. The primary endpoint was AF recurrence within 12 months.
Heart failure and atrial fibrillation patients with iron deficiency.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intravenous ferric carboxymaltose (FCM) on atrial fibrillation (AF) recurrence following electrical cardioversion in patients with heart failure and iron deficiency .
Atrial Fibrillation Recurrence
Time frame: one year
Plan to share: No — "Data will be made available upon reasonable request."
Ran from Jan 2021 to primary completion in Apr 2025, 51 months.
Of 796 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's 51 months is above that.
Counting every sponsor, half of 978 studies reached it within 41 months; a quarter within 22 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bursa Postgraduate Hospital